Advanced Solid Tumors Clinical Trials

1103 clinical trials for Advanced Solid Tumors across international registries, including 318 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• First in Human Study of TUB-030 in Patients With Advanced Solid Tumors — RECRUITING · PHASE1
• A Phase I Study of CS5007 in Participants With Advanced Solid Tumors — RECRUITING · PHASE1
• A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors — RECRUITING · PHASE1
• Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors — RECRUITING · PHASE1
• Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors — RECRUITING · PHASE1
• TT-702 in Patients With Advanced Solid Tumours. — RECRUITING · PHASE1
• A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation. — RECRUITING · PHASE1
• A Study of PHST001 in Advanced Solid Tumors — RECRUITING · PHASE1
• A Phase Ib/II, Multicenter, Open-Label Study to Evaluate Safety, Efficacy, and Pharmacokinetics of YL201 in Combination with Other Anti-Cancer Therapies in Patients with Advanced Solid Tumors — RECRUITING · PHASE2
• A Phase 1 Study to Investigate FP008 in Subjects With Advanced Solid Tumors — RECRUITING · PHASE1
• A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors — RECRUITING · PHASE1
• Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors — RECRUITING · PHASE1
• A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors — RECRUITING · PHASE1
• A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy — RECRUITING · PHASE1
• A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors — RECRUITING · PHASE2
• A Study of PHN-012 in Patients With Advanced Solid Tumors — RECRUITING · PHASE1
• A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors. — RECRUITING · PHASE1
• A Study of GC101 TIL in Advanced Solid Tumors (TR) — RECRUITING · PHASE1
• Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002 — RECRUITING · PHASE1
• A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors — RECRUITING · PHASE1
• Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors — RECRUITING · PHASE1
• Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors — RECRUITING · PHASE1
• A Study of BG-C477 in Participants With Advanced Solid Tumors — RECRUITING · PHASE1
• Study of GS-2426 in Participants With Advanced Solid Tumors — RECRUITING · PHASE1
• A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001) — RECRUITING · PHASE1
• Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations — RECRUITING · PHASE1
• RVU120 Rollover Study — RECRUITING · PHASE2
• A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors — RECRUITING · PHASE1
• A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors — RECRUITING · PHASE1
• A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors. — RECRUITING · PHASE1
• A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002) — RECRUITING · PHASE1
• A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors, including Checkpoint Inhibitor Naïve Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors — RECRUITING · PHASE2
• Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma — RECRUITING · PHASE1
• A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors — RECRUITING · PHASE1
• A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation — RECRUITING · PHASE2
• A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
• A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors — RECRUITING · PHASE1
• A Study of ASP1002 in Adults for Treatment of Solid Tumors — RECRUITING · PHASE1
• A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies — RECRUITING · PHASE1
• Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors — RECRUITING · PHASE1
• A Clinical Study of PA5 in Patients With Advanced Solid Tumors — RECRUITING · PHASE1
• Allogeneic WTX-212C in Advanced Solid Tumors — RECRUITING · PHASE1
• Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors — RECRUITING · PHASE1
• Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors — RECRUITING · PHASE1
• A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors — RECRUITING · PHASE1
• A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) — RECRUITING · PHASE2
• First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer — RECRUITING · PHASE1
• A Study of JNJ-87890387 for Advanced Solid Tumors — RECRUITING · PHASE1
• A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors — RECRUITING · PHASE1
• A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation — RECRUITING · PHASE1

Refine this search